Olmesartan HCT Tablet 10/40/12.5 mg

Adult dose

This medication should be taken as one tablet once daily, regardless of meals, with water. It is recommended to take it at the same time every day (e.g., in the morning). The maximum daily dosage of amlodipine/olmesartan medoxomil/hydrochlorothiazide is 10/40/25 mg. Dosage can be adjusted based on blood pressure control status as follows: - 5/20/12.5 mg: for those whose blood pressure is not adequately controlled with the combination of amlodipine/olmesartan medoxomil 5/20 mg.

Child dose

The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established, thus its administration is discouraged.

This drug may cause serious harm or death to the fetus or newborn if used during the second and third trimesters of pregnancy, therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication, similar drugs, pregnant or breastfeeding women, patients with severe hypotension, or those with severely impaired heart or kidney function should not use this drug. Patients with low blood volume or sodium levels may experience hypotensive symptoms when starting this medication, so careful monitoring during administration is necessary. Patients with kidney impairment, those with decreased liver function, certain heart disease patients, and those with systemic lupus erythematosus require special caution when using this drug. Since this medication lowers blood pressure, dizziness or lightheadedness may occur; caution should be exercised when performing dangerous activities such as working at heights or driving. It is necessary to regularly check electrolyte levels and kidney function during the administration of this drug to confirm there are no abnormalities. This medication may cause increased sensitivity of the skin to sunlight, so minimizing sun exposure and using sunscreen when necessary is recommended. Overdosage may result in severe hypotension, palpitations, bradycardia, and other symptoms. If any abnormal symptoms arise, immediate consultation with a healthcare professional is required. This medication may interact with other drugs, so it is essential to inform the healthcare professional of any other medications currently taken, especially when used in conjunction with lithium, non-steroidal anti-inflammatory drugs, and other antihypertensive agents. Use of this drug is not recommended while breastfeeding. If usage is unavoidable, it is safe to discontinue breastfeeding. The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established, thus its administration is discouraged. Elderly patients may have heightened sensitivity to this medication, hence the dosing should be adjusted and closely monitored.

Serious side effects

Hives, severe swelling (edema), difficulty breathing, angioedema, Quincke's edema, Stevens-Johnson syndrome, jaundice, acute kidney failure, renal failure, acute cholecystitis, acute interstitial pneumonia, acute respiratory distress syndrome (ARDS), pulmonary edema, thrombosis, embolism, myocardial infarction, seizures, confusion of consciousness, syncope, convulsions, acute hearing loss, vasculitis (including necrotizing vasculitis), severe allergic reactions, severe skin reactions, breathing problems,

Mild side effects

• Peripheral edema
• headache
• dizziness
• upper respiratory infection
• nasopharyngitis
• urinary tract infection
• sialadenitis
• leukopenia
• thrombocytopenia
• bone marrow suppression

This medication can be sensitive to air and moisture and should therefore be stored in a tightly sealed container. It is recommended to maintain the storage temperature between 1 to 30 degrees Celsius, which will help preserve its efficacy and safety over time.

Appearance

Round film-coated tablet of grayish-red color

Package unit

28 tablets (14 tablets/PTP x 2)/carton